Physician profile
Antoine E Sakr
NPI 1609058106
$16,305.02
in general payments reported to CMS, 2019-2025
12 companies · $1,036 in 2025
The $1,036 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.05 · 2022: $5,065 · 2023: $4,993 · 2024: $5,183 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,600 · Food and Beverage: $1,302 · Travel and Lodging: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,600.00 |
| Food and Beverage | $1,301.77 |
| Travel and Lodging | $309.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $15,490.30 | 2022-2025 | Impella |
| Abbott Laboratories | $196.57 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| Scpharmaceuticals INC. | $157.19 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $87.97 | 2024 | Assure Wcd |
| Boston Scientific Corporation | $74.85 | 2023-2025 | General - Therapies, Vigilant X4 Crt-D |
| Medtronic, INC. | $54.39 | 2022-2025 | Symplicity G3 |
| Novo Nordisk INC | $54.35 | 2024 | Ozempic, Rybelsus |
| Pfizer INC. | $49.51 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $45.35 | 2024 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $41.15 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $38.39 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Sakr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.